Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
130.33
-1.06 (-0.81%)
At close: May 15, 2025, 4:00 PM
132.85
+2.52 (1.93%)
After-hours: May 15, 2025, 7:13 PM EDT
Krystal Biotech Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Krystal Biotech stock ranges from a low of $189 to a high of $245. The average analyst price target of $218.63 forecasts a 67.75% increase in the stock price over the next year.
Price Target: $218.63 (+67.75%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 4 | 4 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $195 → $189 | Strong Buy | Maintains | $195 → $189 | +45.02% | May 7, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $219 | Strong Buy | Maintains | $219 | +68.03% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $240 | Strong Buy | Reiterates | $240 | +84.15% | May 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $221 → $240 | Strong Buy | Maintains | $221 → $240 | +84.15% | Apr 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $221 → $240 | Strong Buy | Maintains | $221 → $240 | +84.15% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
436.15M
from 290.52M
Increased by 50.13%
Revenue Next Year
637.06M
from 436.15M
Increased by 46.06%
EPS This Year
7.15
from 3.00
Increased by 138.31%
EPS Next Year
11.32
from 7.15
Increased by 58.30%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 504.8M | 803.8M | 1.1B | ||
| Avg | 436.2M | 637.1M | 828.9M | ||
| Low | 396.6M | 499.1M | 530.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 73.8% | 84.3% | 79.9% | ||
| Avg | 50.1% | 46.1% | 30.1% | ||
| Low | 36.5% | 14.4% | -16.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.77 | 16.94 | 24.81 | ||
| Avg | 7.15 | 11.32 | 15.10 | ||
| Low | 5.41 | 6.11 | 8.32 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 192.3% | 136.9% | 119.2% | ||
| Avg | 138.3% | 58.3% | 33.5% | ||
| Low | 80.3% | -14.6% | -26.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.